Replikins boasts of new swine flu jab; Gardasil sales flatten in Europe;

Vaccine Research

Boston-based Replikins says that it has already developed a synthetic H1N1 vaccine and can produce it 100 times faster than the competition. Report

Lipoxen PLC has received funding to apply its ImuXen technology to enhance the performance of malaria vaccine candidates. Release

A potential vaccine for Alzheimer's disease also has been shown in mice to slow the weakening of muscles associated with inclusion body myositis, a disorder that affects the elderly. Release

Scientists at Baylor Institute for Immunology Research in Dallas received a renewal of a multi-million dollar grant from the National Institutes of Health to design new vaccines to prevent influenza--including swine flu. Release

Vaccine Market

Sales of Merck's Gardasil are expected to be flat in Europe as demand from early adopter countries levels off. Report

McKesson says that it will store 500,000 doses of flu vaccine for the CDC. Report

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.